Sentinel BioTherapeutics

Sentinel Bio is a biotechnology company pioneering the development of programmable cell therapies using advanced synthetic biology. Founded in 2022 by synthetic biology pioneers Jim Collins and Wilson Wong, the company utilizes sophisticated genetic circuits to create smart cells capable of sensing specific disease environments and delivering localized therapeutic responses. Their primary focus is on overcoming the challenges of treating solid tumors and complex inflammatory conditions by engineering cells with logic-gate capabilities. By enabling cells to perform complex logic, Sentinel Bio aims to improve the precision, safety, and efficacy of next-generation cell-based medicines. The company is currently in the pre-clinical stage and is backed by prominent life science investors including 5AM Ventures and Roche Venture Fund.